COMPOSITION: Micronized, purified flavonoid fraction 500 mg: 450 mg diosmin; 50 mg flavonoids expressed as hesperidine. Micronized, purified flavonoid fraction 1000 mg: 900 mg diosmin; 100 mg flavonoids expressed as hesperidine.

INDICATIONS: Treatment of the symptoms related to venolymphatic insufficiency (heavy legs, pain, early morning restless legs). Treatment of functional symptoms related to acute hemorrhoidal attack.

DOSAGE AND ADMINISTRATION: In venous disease: 1000 mg daily. In acute hemorrhoidal attacks: the dosage can be increased up to 3000 mg daily.

CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients.

WARNINGS: The administration of this product for the symptomatic treatment of acute hemorrhoids does not preclude treatment for other anal conditions. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed.

FERTILITY / PREGNANCY / LACTATION: Treatment should be avoided.

DRIVE & USE MACHINES: Negligible influence on these abilities.

UNDESIRABLE EFFECTS: Common: diarrhoea, dyspepsia, nausea, vomiting. Rare: dizziness, headache, malaise, rash, pruritus, urticaria. Uncommon: colitis. Frequency not known: abdominal pain, isolated face, lip, eyelid oedema. Exceptionally Quincke’s oedema.

OVERDOSE PROPERTIES: Vasoprotectives/Capillary stabilising agents/Bioflavonoids. Daflon acts on the vascular return system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance.

PRESENTATION: Pack of 30 film-coated tablets of Daflon 500 mg. Pack of 10 or 30 film-coated tablets of Daflon 1000 mg.

www.servier.com 170522* For complete information, please refer to the Summary of Product Characteristics for your country. Please refer to full prescribing information before prescribing.